NCT04840602 2026-06-03Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaNational Cancer Institute (NCI)Phase 2 Recruiting92 enrolled